The Long Run with Luke Timmerman Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
Jan 22, 2026
Ron Renaud, CEO of Kylara Therapeutics and seasoned biotech leader, shares insights on developing GLP-1 medicines designed to combat obesity. He discusses the pivotal moment for GLP-1 treatments, highlighting impressive phase 2 results of rebupatide and its unique advantages over competitors. Renaud explains the significance of tolerability and market differentiation while outlining Kylara's focus on high-BMI patients. The conversation also touches on the societal impact of obesity treatments and the promising potential within this evolving healthcare landscape.
AI Snips
Chapters
Transcript
Episode notes
Multiple Routes Are Strategic Shots On Goal
- The original asset set included multiple mechanisms and both injectable and oral routes.
- Ron viewed multiple administration options as strategic 'shots on goal' to address patient needs.
Diligence And Onshore Execution Matter
- Do rigorous diligence when licensing assets from China and align regulatory and supply strategies to Western standards.
- Ron emphasizes U.S.-based CDMOs, U.S. employees, and Western regulatory alignment to reassure payers and partners.
Focus On Your Execution, Not The Noise
- In a noisy competitive field, focus on executing your own program and designing strategic trials.
- Ron says Kylara stays laser-focused on enrolling phase 3 studies for its lead agent rather than chasing every competitor signal.